84 related articles for article (PubMed ID: 7705748)
1. Significance of 2',5'-oligoadenylate synthetase activity and HCV genotype in IFN therapy for type C chronic hepatitis.
Karino Y; Hige S; Matsushima T; Miyazaki T; Toyota J
Hokkaido Igaku Zasshi; 1994 Nov; 69(6):1354-9. PubMed ID: 7705748
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of the effect of interferon (IFN) therapy in patients with type B and C chronic hepatitis].
Karino Y
Hokkaido Igaku Zasshi; 1993 May; 68(3):297-309. PubMed ID: 7686526
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells.
Grandér D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Björklund AC; Befrits R; Björkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
Scand J Gastroenterol; 1996 Jun; 31(6):604-11. PubMed ID: 8789901
[TBL] [Abstract][Full Text] [Related]
4. [2-5 AS activity in serum and peripheral blood mononuclear cells for chronic active hepatitis C and the relationship to clinical outcome of interferon therapy].
Toda K; Kumagai N; Iwabuchi N; Suzuki T; Saito H; Morizane T; Hibi T; Ishii H; Tsuchimoto K
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Oct; 20(5):428-36. PubMed ID: 9391306
[TBL] [Abstract][Full Text] [Related]
5. Effect of interferon treatment on serum 2',5'-oligoadenylate synthetase levels in hepatitis C-infected patients.
Murashima S; Kumashiro R; Ide T; Miyajima I; Hino T; Koga Y; Ishii K; Ueno T; Sakisaka S; Sata M
J Med Virol; 2000 Oct; 62(2):185-90. PubMed ID: 11002247
[TBL] [Abstract][Full Text] [Related]
6. Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load.
Arase Y; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Kobayashi M; Sezaki H; Ikeda K; Kumada H
Intervirology; 2004; 47(1):19-25. PubMed ID: 15044832
[TBL] [Abstract][Full Text] [Related]
7. Serum 2'-5'oligoadenylate synthetase as a monitoring marker of anti-viral effect during interferon therapy for chronic type B hepatitis.
Karino Y; Sugawara T; Saga A; Yoshida J; Matsushima T; Miyazaki T; Toyota J; Okuuchi Y
Gastroenterol Jpn; 1989 Apr; 24(2):164-9. PubMed ID: 2744332
[TBL] [Abstract][Full Text] [Related]
8. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
[TBL] [Abstract][Full Text] [Related]
9. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
[TBL] [Abstract][Full Text] [Related]
10. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated type C cirrhosis.
Saito T; Shinzawa H; Kuboki M; Ishibashi M; Toda H; Okuyama Y; Nakamura T; Yamada N; Wakabayashi H; Togashi H
Am J Gastroenterol; 1994 May; 89(5):681-6. PubMed ID: 8172137
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
[TBL] [Abstract][Full Text] [Related]
13. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes.
Hopf U; Berg T; König V; Küther S; Heuft HG; Lobeck H
J Hepatol; 1996; 24(2 Suppl):67-73. PubMed ID: 8836892
[TBL] [Abstract][Full Text] [Related]
15. [Examination in clinical course of HCV in interferon treatment].
Kumada H
Nihon Rinsho; 1994 Jul; 52(7):1832-5. PubMed ID: 7521426
[TBL] [Abstract][Full Text] [Related]
16. [Serum levels of HCV-RNA determined by branched DNA (bDNA) probe assay in chronic hepatitis C: method and clinical significance on interferon (IFN) therapy].
Osada T; Iwabuchi S; Takatori M; Murayama M; Iino S
Nihon Rinsho; 1994 Jul; 52(7):1747-53. PubMed ID: 7521414
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C.
Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagata T; Tamaki J; Azuma M; Kishida Y; Yoshida A; Hikiji AY
Hepatogastroenterology; 1995; 42(5):535-41. PubMed ID: 8751211
[TBL] [Abstract][Full Text] [Related]
18. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.
Lam NP; Pitrak D; Speralakis R; Lau AH; Wiley TE; Layden TJ
Dig Dis Sci; 1997 Jan; 42(1):178-85. PubMed ID: 9009135
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
Martinot-Peignoux M; Marcellin P; Pouteau M; Castelnau C; Boyer N; Poliquin M; Degott C; Descombes I; Le Breton V; Milotova V
Hepatology; 1995 Oct; 22(4 Pt 1):1050-6. PubMed ID: 7557850
[TBL] [Abstract][Full Text] [Related]
20. [Interferon therapy for acute hepatitis C; changes in serum markers associated with HCV and clinical effects].
Fukui S; Tohyama H; Iwabuchi S
Nihon Rinsho; 1994 Jul; 52(7):1847-51. PubMed ID: 7521429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
